🏛️ Verified NIH Record • Updated 2026-08-17
(TNX-1500) in Kidney Transplant Recipients (NCT07204080)
Phase II Clinical Trial Evaluating the Safety Efficacy of Fc-Modified Anti-CD154 mAB (TNX-1500) in Kidney Transplant Recipients
🟡 Not Yet Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: Ayman Al Jurdi, MD
🩺 Plain-English Summary (8th-Grade Level)
The primary objective is to investigate the safety of TNX-1500, an FC-modified anti-CD154 mAb, in five kidney transplant recipients at 12 months.
Who can join: Review the eligibility criteria below.
Location: Massachusetts General Hospital — Boston, Massachusetts
Age range: 18 Years to 75 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (2 Sites)
- Massachusetts General Hospital — Boston, Massachusetts
- Massachusetts General Hospital — Boston, Massachusetts
📞 Contact the Study Coordinator
Phone: (617) 726-2000
Email: aaljurdi@mgh.harvard.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Kidney Transplant
- Allogeneic Regulatory Dendritic Cell (DCreg) Renal Study — Pittsburgh, Pennsylvania
- Pro-active Genetic Testing in Kidney Transplant Patients — Scottsdale, Arizona
- Dapagliflozin in Living-Donor Kidney Transplant Recipients — Guadalajara, Jalisco
- Phenotype Guided Vasoactive Medication During Kidney Transplantation — Los Angeles, California
- GraftAssure Lowering Allograft rejeCTIon by Combination- (GALACTIC) Trial — Livingston, New Jersey
- Letermovir for R+ Study — Madison, Wisconsin
Explore by condition: All Kidney Transplant clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.